Reprogrammed Interchange Llc Sells 15,000 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 300,000 shares for $525,000, indicating a 0.88% decrease in their stake.
• Vor Biopharma's stock traded down to $1.60, with a market capitalization of $202.69 million and a twelve-month high of $3.29.
• Wall Street analysts have a consensus rating of "Moderate Buy" for VOR shares, with a target price of $6.07 as several firms restated positive ratings.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 15,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00. Following the completion of the sale, the insider owned 1,681,424 shares of the company's stock, valued at $58,849,840. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The stock was sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $898,440.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $39.40, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 22,650 shares of Vor Biopharma stock. The stock was sold at an average price of $38.60, for a total transaction of $874,290.00.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 27,730 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $1,109,200.00.

Vor Biopharma Trading Down 10.4%

Shares of NYSE:VOR traded down $3.16 during trading on Friday, hitting $27.24. 654,392 shares of the company's stock were exchanged, compared to its average volume of 380,475. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The firm has a 50-day moving average price of $40.37 and a two-hundred day moving average price of $22.88. The firm has a market cap of $3.45 billion, a P/E ratio of -16.51 and a beta of 2.05.

Analyst Ratings Changes

VOR has been the subject of a number of analyst reports. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Vor Biopharma presently has a consensus rating of "Moderate Buy" and an average target price of $121.33.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in Vor Biopharma in the first quarter valued at approximately $140,000. Two Sigma Investments LP lifted its stake in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after buying an additional 25,930 shares in the last quarter. Northern Trust Corp lifted its stake in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Vor Biopharma in the first quarter worth $100,000. Finally, Trustees of Columbia University in the City of New York bought a new stake in shares of Vor Biopharma in the fourth quarter worth $102,000. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.